Article Contents ::
- 1 The Brand Name AMIT Has Generic Salt :: Amitriptyline
- 2 AMIT Is From Company Mano Priced :: Rs. 11.5
- 3 AMIT have Amitriptyline is comes under Sub class Anti Depressants of Main Class Nervous System
- 4 Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Depressants
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name AMIT Has Generic Salt :: Amitriptyline
AMIT Is From Company Mano Priced :: Rs. 11.5
AMIT have Amitriptyline is comes under Sub class Anti Depressants of Main Class Nervous System
Main Medicine Class:: Nervous System Sub Medicine Class :: Anti Depressants
| Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
| Amitriptyline | TAB | Rs. 11.5 | 10 |
| Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
| AMIT | Mano | 10 MG | 10 | Rs. 11.5 |
| Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
| From Mano :: AMIT | Amitriptyline | Nervous System | Anti Depressants |
Indications for Drugs ::
Migraine headache, Depression, Neuropathic pain, Post-herpetic neuralgia, Nocturnal enuresis
Drug Dose ::
Adult: PO Depression Initial:50-75 mg/day; up to 150 mg/day if needed. Max: 300 mg/day in severe cases. Child: Adolescent: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. Elderly: Initially, 25-50 mg/day as a single dose (at bedtime) or in divided doses. Neuropathic pain Initial: 10-25 mg/day at night, up to 75 mg/day if needed. Migraine prophylaxis Initial: 10 mg/day at night. Maintenance: 50-75 mg/day at night. Nocturnal enuresis Child: 6-10 yr 10-20 mg/day; 11-16 yr 25-50 mg/day. All doses to be given at bedtime. Max duration: 3 mth.
Contraindication ::
Hypersensitivity, use of MAO inhibitors within the last 14 days; acute recovery phase post-MI. Concurrent usage with cisapride.
Drug Precautions ::
Bipolar illness, pregnancy, lactation elderly, CVS disease, renal or liver impairment, epilepsy, thyroid dysfunction, DM. Avoid abrupt withdrawal; urinary retention, prostatic hyperplasia; chronic constipation; angle-closure glaucoma; phaeochromocytoma. Monitor for signs of clinical worsening, suicidality or behavioural changes. May increase risks associated with electro-convulsive therapy. May affect ability to drive or operate machinery.
Drug Side Effects ::
Postural hypotension, tachycardia, conduction disturbances. Dry mouth, wt gain, sour or metallic taste, stomatitis, constipation; blurring of vision, urinary retention, fatigue, dizziness, weakness, tremors, headache, confusion and delirium in elderly, sexual disturbances; peripheral neuropathy; urticaria, angioedema, sweating. Potentially Fatal: Cardiac arrhythmias.
Pregnancy category ::
3
Drug Mode of Action ::
Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant. It increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin.
Drug Interactions ::
Increased risk of serotonin syndrome w/ SSRIs, TCAs, triptans, fentanyl, lithium, tramadol. May reduce plasma levels w/ barbiturates, rifampicin and other anticonvulsants. May increase plasma levels w/ methylphenidate, cimetidine, antipsychotics, Ca channel blockers. May precipitate cardiac arrhythmias w/ thyroid hormones. May reduce antihypertensive effects of debrisoquine, guanethidine and clonidine. May increase pressor effect of epinephrine and norepinephrine. May increase the risk of ventricular arrhythmias w/ antiarrhythmics (e.g. amiodarone or quinidine), antihistamines astemizole, terfenadine, some antipsychotics (pimozide, sertindole, and thioridazine), sotalol, cisapride and halofantrine. Potentially Fatal: Increased risk of serotonin syndrome w/ MAOIs, linezolid and methylene blue.
